Corrigendum to "Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations" [<i>Kidney International Reports</i> Volume 9, Issue 9, September 2024, Pages 2608-2618].
對於「Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations」的更正 [<i>Kidney International Reports</i> 第9卷，第9期，2024年9月，頁2608-2618]。
Kidney Int Rep 2025-04-14
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理：使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關的問題，請提供更多細節！
PubMedDOI
Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations.
心血管-腎臟-代謝綜合症中心血管、腎臟及代謝疾病的結合，及新的風險預測方程式。
Kidney Int Rep 2024-09-18
Corrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].
對於「Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes」的更正 [J. Clin. Translat. Endoc. 36C (2024) 100343]。
J Clin Transl Endocrinol 2025-01-07
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
Corrigendum to "POS-074 SERUM NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN, EARLY BIOMARKER OF ACUTE KIDNEY INJURY IN ASPHYXIATED TERM NEONATES AT LAGOS STATE UNIVERSITY TEACHING HOSPITAL" [<i>Kidney International Reports</i> Volume 7, Issue 2, Supplement, February 2022, Page S31].
對於「POS-074 SERUM NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN, EARLY BIOMARKER OF ACUTE KIDNEY INJURY IN ASPHYXIATED TERM NEONATES AT LAGOS STATE UNIVERSITY TEACHING HOSPITAL」的更正 [<i>Kidney International Reports</i> 第7卷，第2期，補充，2022年2月，第S31頁]。
Kidney Int Rep 2025-02-24
Corrigendum to "Avoid Preanalytical Errors When Using Urine Biomarkers of Exposure" [<i>Kidney International Reports</i> Volume 10, Issue 1, January 2025, Page 281].
對於「避免在使用尿液暴露生物標記時產生前分析錯誤」的更正 [<i>Kidney International Reports</i> 第10卷，第1期，2025年1月，第281頁]。
Kidney Int Rep 2025-04-14
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056].
「『Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome』一文的勘誤啟事」
Kidney Int Rep 2025-04-30
**重點摘要：**
這份聲明列出了在期刊「Kidney International Reports」中多篇文章的更正，每篇文章都以其 DOI 作為識別。這些更正主要是針對原始發表內容中的錯誤或需要更新的資訊所做的修正。
PubMedDOI
Erratum to "Advancing Understanding of Mitochondrial Function in Diabetic Kidney Disease" [<i>Kidney International Reports</i> Volume 10, Issue 2, February 2025, Pages 285-286].
「更正啟事：『推進對糖尿病腎病變中線粒體功能的理解』［Kidney International Reports 第10卷第2期，2025年2月，頁285-286］」
Kidney Int Rep 2025-07-09
這則通知是針對 DOI 10.1016/j.ekir.2024.12.001 的文章做更正，主要是修正原文的錯誤或補充最新資訊。詳細內容請直接參考該篇文章的更正說明。
PubMedDOI